Regulation (EC) No 2037/2000 ANNEX II

ANNEX IISupplementary provisions

ANNEX II ESSENTIAL MEDICAL USES Quota of controlled substances of Group I that may be used in the production of metered-dose inhalers (MDIs) for the treatment of asthma and other chronic obstructive pulmonary diseases (COPDs) are allocated to: 3M (UK) Aventis (UK) Bespak (UK) Boehringer Ingelheim (DE) Chiesi (IT) Glaxo Smith Kline (UK) IG Sprühtechnik (DE) Inyx Pharmaceuticals (UK) IVAX (IE) Jaba Farmaceutica (PT) Lab. Aldo-Union (ES) Otsuka Pharmaceuticals (ES) Sicor (IT) Schering-Plough (BE) V.A.R.I. (IT) Valeas (IT) Valois (FR)

Read the full instrument →

Other provisions in Regulation (EC) No 2037/2000

Compiled from an official source version. Later amendments or repeals may not be reflected; the official text prevails. · Read the official text ↗ · Data as of 2026-07-04

CitationANNEX II of Regulation (EC) No 2037/2000 (LawPlayer, data as of 2026-07-04)

What to look at next

Regulation (EC) No 2037/2000, full textThe complete text of this law, so you can read this section in contextEuropean Union legislation EU Legal Acts by type and yearGrouped by instrument type and year of enactment, so you can find others of the same kindBrowse by type and year European Union: what this database coversWhich datasets are here, which official source they come from, and how current they areEuropean Union overview